Related Experiment Video
Updated: Jun 6, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
[Transitional cell carcinoma of the prostate]
Urologia
|November 19, 2010
Summary
Transitional cell carcinoma of the prostate (TCCP) is increasingly recognized as part of urothelial disease. Early diagnosis and appropriate treatment, ranging from conservative measures to radical cystectomy, are crucial for managing TCCP based on invasion depth.
Area of Science:
- Uro-oncology
- Pathology
Context:
- Transitional cell carcinoma of the prostate (TCCP) is an increasingly recognized entity.
- TCCP is associated with the broader category of pan-urothelial disease.
- Urologists must consider the prostate in bladder cancer management.
Purpose:
- To highlight the diagnostic and management considerations for TCCP.
- To emphasize the relationship between TCCP and bladder cancer.
- To discuss treatment strategies based on TCCP invasiveness.
Summary:
- TCCP incidence is rising due to increased awareness.
- Secondary TCCP occurs with bladder cancer; primary TCCP is rare.
- Prognosis and treatment depend on the degree of prostate invasion.
- Non-invasive TCCP is managed conservatively (TUR +/- BCG).
- Stromal invasive TCCP requires aggressive treatment (radical cystectomy).
- TCCP can complicate urinary diversion decisions post-cystectomy.
Impact:
- Improved recognition of TCCP within uro-oncology.
- Guidance for urologists in managing TCCP and associated urothelial cancers.
- Informed treatment decisions based on TCCP staging and invasion.
- Potential for better patient outcomes through tailored therapeutic approaches.
